Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?
Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Séamus O’Reilly · 2026
Read Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? by Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Séamus O’Reilly (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13569557.txt.
Description
Edel Burton and co-authors argue, in a 2026 commentary, that Ireland is missing savings by using few biosimilar drugs in cancer care. Biologic medicines transformed treatment for many serious diseases. Yet cancer drug spending in Irish hospitals climbed from under five million euros in 2013 to over one hundred fifty million a decade later, part of a global surge.
Biosimilars, near-copies approved as equally safe and effective, could cut that burden and widen access. Uptake in Ireland stays low and uneven between hospitals, held back by pharmacy substitution resistance and new patented formats. The authors press health leaders to close the gap before rising cancer cases strain budgets further.
Catalog record
| CREATOR | Edel Burton, Kate E. Coakley, Siobhán Gaynor, Mei McDonagh, Christopher Palmer, Laura J. Sahm, Séamus O’Reilly |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26372 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |